OssDsign reported second-quarter net sales of SEK 37.8 million, an 18.7% decline from SEK 46.5 million a year earlier, while the adjusted operating loss widened to SEK -12.0 million from SEK -6.2 million. The Stockholm-listed medical device company, which focuses on cranial reconstruction implants, said the revenue outcome was in line with its guidance to the market.
Gross profit fell to SEK 34.8 million from SEK 45.0 million, pushing the gross margin down to 92.1% from 96.8% in Q2 2025. Reported operating loss came in at SEK -12.3 million versus SEK -6.9 million, and the net loss after tax was SEK -11.4 million, or SEK -0.1 per share, compared with SEK -8.3 million a year earlier.
CEO Mark Waugh acknowledged the weaker top line but pointed to sequential improvement and ongoing work to strengthen the company's fundamentals for a return to growth. He also flagged the usual seasonal impact of U.S. summer holidays in July and August as a headwind for the third quarter, while expressing confidence that the company's efforts will yield concrete results later in the year.
The share price fell around 6% on the day of the release, extending a year-to-date decline of roughly 64%. TradingView's summary of the interim report noted that revenue was flat sequentially but down year-over-year due to prior large orders and currency effects, with gross margin improving from Q1 but remaining below last year's level.